Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer

Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Rosenberg, 2001, Progress in human tumour immunology and immunotherapy, Nature, 411, 380, 10.1038/35077246 Chen, 2015, Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer, Br J Cancer, 112, 1088, 10.1038/bjc.2015.61 Li, 2014, Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis, Int J Cancer, 134, 2403, 10.1002/ijc.28536 Zhang, 2017, Oncotarget, 8, 57516, 10.18632/oncotarget.15497 Rossi, 2017, Are markers of systemic inflammation good prognostic indicators in colorectal cancer?, Clin Colorectal Cancer, 16, 264, 10.1016/j.clcc.2017.03.015 Roxburgh, 2010, Role of systemic inflammatory response in predicting survival in patients with primary operable cancer, Future Oncol, 6, 149, 10.2217/fon.09.136 Chua, 2011, Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer, Br J Cancer, 104, 1288, 10.1038/bjc.2011.100 Kim, 2018, Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response, Asia Pac J Clin Oncol, 14, 239, 10.1111/ajco.12784 Halazun, 2008, Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases, Eur J Surg Oncol, 34, 55, 10.1016/j.ejso.2007.02.014 Ishizuka, 2009, Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer, J Surg Oncol, 100, 38, 10.1002/jso.21294 Song, 2017, The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer, BMC Cancer, 17, 744, 10.1186/s12885-017-3752-0 Formica, 2014, Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients, Med Oncol, 31, 166, 10.1007/s12032-014-0166-6 Dell’Aquila, 2018, Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO, Ann Oncol, 29, 924, 10.1093/annonc/mdy004 Sauerbrei, 2018, Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): an abridged explanation and elaboration, J Natl Cancer Inst, 110, 803, 10.1093/jnci/djy088 Dirican, 2014, Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?, Asian Pac J Cancer Prev, 15, 4781, 10.7314/APJCP.2014.15.12.4781 Yang, 2017, Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS, Sci Rep, 7, 17166, 10.1038/s41598-017-17130-6 Kishi, 2009, Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy, Ann Surg Oncol, 16, 614, 10.1245/s10434-008-0267-6 Chiang, 2012, Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively?, Int J Colorectal Dis, 27, 1347, 10.1007/s00384-012-1459-x Nagasaki, 2015, Prognostic impact of neutrophil-to-lymphocyte ratio in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy, Dig Surg, 32, 496, 10.1159/000441396 Grenader, 2016, Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study, Br J Cancer, 114, 612, 10.1038/bjc.2016.23 Kubo, 2014, Impact of the perioperative neutrophil-to-lymphocyte ratio on the long-term survival following an elective resection of colorectal carcinoma, Int J Colorectal Dis, 29, 1091, 10.1007/s00384-014-1964-1 Sunakawa, 2016, Immune-related genes to predict clinical outcome of cetuximab (cet) treatment for metastatic colorectal cancer (mCRC): immuno-Oncology assay research, J Clin Oncol, 34, 11591, 10.1200/JCO.2016.34.15_suppl.11591 Moghaddam, 1995, Thymidine phosphorylase is angiogenic and promotes tumor growth, Proc Natl Acad Sci U S A, 92, 998, 10.1073/pnas.92.4.998 Akiba, 2008, N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma, Oncol Rep, 20, 1329 Sanchez-Espiridion, 2009, A TaqMan low-density array to predict outcome in advanced Hodgkin’s lymphoma using paraffin-embedded samples, Clin Cancer Res, 15, 1367, 10.1158/1078-0432.CCR-08-1119 Barros, 2013, Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages, PLoS One, 8, e80908, 10.1371/journal.pone.0080908